Recent investigations have focused on the overlap of GLP|GIP|glucagon receptor stimulant therapies and dopaminergic signaling. While GLP agonists are increasingly employed for addressing type 2 diabetes mellitus, their emerging consequences on motivation circuits, specifically influenced by dopamine networks, are attracting substantial focus. This